Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia

PHASE3CompletedINTERVENTIONAL
Enrollment

404

Participants

Timeline

Start Date

April 9, 2019

Primary Completion Date

September 23, 2021

Study Completion Date

September 23, 2021

Conditions
Secondary Hyperparathyroidism
Interventions
DRUG

KHK7580

oral administration

DRUG

Cinacalcet Hydrochloride

oral administration

Trial Locations (34)

Unknown

Research site_29, Changsha

Research site_34, Dalian

Research site_25, Foshan

Research site_22, Guangzhou

Research site_23, Guangzhou

Research site_30, Guangzhou

Research site_28, Hefei

Research site_32, Nanjing

Research site_33, Nanjing

Research site_24, Shanghai

Research site_26, Shanghai

Research site_27, Shanghai

Research site_31, Wuxi

Research site_11, Hong Kong

Research site_21, Anyang

Research site_13, Daegu

Research site_15, Daegu

Research site_12, Goyang

Research site_18, Incheon

Research site_14, Seoul

Research site_17, Seoul

Research site_19, Seoul

Research site_20, Seoul

Research site_16, Ulsan

Research site_2, Kaohsiung City

Research site_3, Kaohsiung City

Research site_5, Kaohsiung City

Research site_9, Taichung

Research site_4, Tainan City

Research site_7, Tainan City

Research site_10, Taipei

Research site_1, Taipei

Research site_6, Taipei

Research site_8, Taipei

All Listed Sponsors
collaborator

Kyowa Kirin China Pharmaceutical Co., Ltd.

INDUSTRY

collaborator

Kyowa Kirin Korea Co., Ltd.

INDUSTRY

lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT03822507 - Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia | Biotech Hunter | Biotech Hunter